Overview

Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)

Status:
Terminated
Trial end date:
2021-02-25
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study to investigate the safety and efficacy of ATI-450 for the Maintenance of Remission in Patients with Cryopyrin-Associated Periodic Syndrome (CAPS) Previously Managed with Anti-IL-1 Therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Aclaris Therapeutics, Inc.